Article: Mithridion Announces Progress With Drugs for Alzheimer's Disease and Schizophrenia.

New Product Options in Development, plus Evidence of Disease-Modifying Potential CEO To Present at the 7th Annual MidAmerica Healthcare Venture Forum

MADISON, Wis., Nov 12 /PRNewswire/ -- Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia. New product options have been developed for MCD-386, a clinical-stage drug candidate with "first-in-class" potential for improving memory and cognition in AD, improving cognition in schizophrenia, and for disease-modifying ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!